Nested Gravastars, Laser-Enhanced Protein Imaging, and the Genomics of Human Knockouts

Nested Gravastars, Laser-Enhanced Protein Imaging, and the Genomics of Human Knockouts
Three landmark studies challenge established limits — of general relativity, of electron microscopy resolution, and of drug discovery methodology. Frankfurt's Jampolski and Rezzolla solve Einstein's field equations for nested gravastars — compact stellar remnants with dark-energy interiors hosting isotropic mini-universes, resolving black hole singularities without exotic physics; UC Berkeley and CZ Biohub integrate a continuous-wave laser phase plate into cryo-EM, boosting image contrast enough to resolve proteins as small as 10 kDa (90% of the human proteome previously invisible); and the Pakistan Genome Resource (173,303 individuals) maps natural human knockouts across 6,500 genes — providing a direct human safety database for drug target validation before clinical trials.
🔭 Nested Gravastars — A Singularity-Free Black Hole Alternative
The Black Hole Singularity Problem
Why singularities are physically unacceptable: General relativity's field equations predict that when a sufficiently massive star collapses, all its mass concentrates at a point of infinite density (the singularity). At a singularity:
- Spacetime curvature is infinite
- All physical quantities (density, temperature, pressure) diverge to infinity
- The known laws of physics (including general relativity itself) break down — GR predicts its own failure
Physicists widely agree that singularities indicate the breakdown of the theory rather than a real physical state. Something — presumably quantum gravity — prevents singularities from forming. But no complete quantum gravity theory exists.
Proposed singularity-free alternatives:
| Alternative | Interior | Observational Distinction from BH |
|---|---|---|
| Standard black hole | Singularity (infinite density) | None (singularity is hidden by event horizon) |
| Gravastar | Dark energy core (negative pressure, de Sitter interior) | Minimal — similar exterior; no event horizon |
| Nestar (nested gravastar) | Dark energy core + inner gravastar(s) | No event horizon; possible GW echo signals |
| Fuzzballs (string theory) | String excitations fill interior | GW echoes at late ringdown times |
| Regular black holes (Bardeen) | Non-singular, quantum-modified core | GW ringdown modification |
The Jampolski-Rezzolla Solution — How Nestars Form
The stellar collapse pathway in the Jampolski-Rezzolla model:
| Stage | Physics | Duration |
|---|---|---|
| Initial collapse | Gravitational collapse of massive star core | Hours–days |
| Critical threshold | Density reaches quantum-gravity critical density (~Planck density: 5×10⁹⁶ kg/m³) | Instantaneous |
| Phase transition | Ordinary matter undergoes first-order phase transition to dark energy state | Instantaneous |
| Dark energy core formation | Interior becomes de Sitter spacetime (constant positive energy density, negative pressure) | — |
| Shell formation | Thin shell of ordinary matter at the phase boundary | — |
| Gravastar stability | Dark energy interior pushes outward; shell self-gravity holds equilibrium | Stable (theoretically indefinitely) |
| Nested gravastar | If shell density is also above critical threshold → inner shell undergoes same transition → nested gravastar forms | Recursive |
The interior "mini-universe" — what the mathematics shows: The de Sitter interior of a gravastar is described by the metric:
- Isotropic (same in all directions)
- Expanding (exponential expansion driven by dark energy's negative pressure)
- Homogeneous (uniform energy density)
These three properties exactly match the properties of our own observable universe as described by the FLRW metric (Friedmann-Lemaître-Robertson-Walker). The gravastar interior is, mathematically, an expanding cosmology — a mini-universe.
Key mathematical results from the Frankfurt paper:
| Result | Value/Finding | Significance |
|---|---|---|
| Stable gravastar mass range | 1.4–100 M☉ (solar masses) | Spans neutron star → stellar black hole mass range |
| Nestar (nested) stability | Requires ≥2 shells with specific mass ratios | Not all gravastars form nestars |
| Outermost radius | Identical to Schwarzschild radius: r = 2GM/c² | Externally indistinguishable from black hole |
| No event horizon | Confirmed — no null surface where escape velocity = c | Resolves information paradox |
| GW echo prediction | Echoes at t ≈ 0.1–1 × 10⁶ × r_s/c after merger | Potentially detectable by LISA (2030s) |
Observational tests — how to distinguish gravastars from black holes: Because the exterior spacetime is identical, electromagnetic observations cannot distinguish them. However:
- Gravitational wave ringdown echoes: After a compact object merger, a black hole emits a ringdown signal that decays. A gravastar's reflective surface (the shell) would reflect GW energy back outward, creating "echoes" at late times (seconds after merger). LIGO data has been analysed for echoes — marginal hints found but not confirmed. LISA's lower-frequency sensitivity (10⁻⁴ to 10⁻¹ Hz) may be more sensitive to gravastar echo signatures.
⚡ UC Berkeley Laser Phase Plate — Cryo-EM Enters the Small Protein Era
The Cryo-EM Contrast Problem
Why small proteins are invisible in cryo-EM: When the electron beam passes through a biological sample, the contrast comes from phase shifts — electrons scattered by the protein travel slightly different paths than unscattered electrons, and the interference creates contrast. For large proteins (>70 kDa), the total phase shift is detectable. For small proteins:
| Protein Size | Molecular Weight | Phase Shift | Cryo-EM Detectability |
|---|---|---|---|
| Large (e.g., ribosome) | 2,500 kDa | Large | Excellent |
| Medium (e.g., proteasome) | 700 kDa | Moderate | Good |
| Small (e.g., ubiquitin) | 8.5 kDa | Tiny (~λ/1000) | Previously impossible |
| Very small (e.g., insulin) | 5.8 kDa | Negligible | Previously impossible |
~90% of human proteins are below 70 kDa — most of the proteome has been invisible to cryo-EM.
Why phase contrast works (the Nobel Prize principle): Phase-contrast microscopy (Nobel 1953, Zernike) converts invisible phase shifts into visible intensity differences by introducing a physical phase shift to the unscattered beam — making the interference between scattered and unscattered electrons constructive instead of destructive.
For cryo-EM: this requires shifting the phase of the unscattered electrons by exactly π/2. Previous attempts used thin carbon phase plates — but carbon plates accumulated charge and degraded after minutes of use.
The Laser Phase Plate Solution
How the UC Berkeley laser phase plate works:
| Component | Specification | Function |
|---|---|---|
| Laser source | CW 1,064nm Nd:YAG laser | Continuous-wave (not pulsed) for stable phase shift |
| Optical cavity | High-finesse Fabry-Pérot cavity (finesse F > 100,000) | Recirculates laser power; achieves ~1 MW/cm² intracavity intensity |
| Beam waist | ~10 μm diameter at electron beam crossing | Matches cryo-EM column geometry |
| Electron beam crossing | Unscattered beam passes through laser focus; scattered beam bypasses | Applies phase shift selectively to unscattered electrons only |
| Phase shift achieved | π/2 (quarter-wave shift) | Converts phase contrast to amplitude contrast |
| Stability | No physical material in beam → no charging, no degradation | Stable for hours (vs minutes with carbon plates) |
Results — resolution improvements:
| Protein | Molecular Weight | Previous best resolution (no phase plate) | With laser phase plate |
|---|---|---|---|
| Haemoglobin | 64 kDa | 3.4 Å | 1.9 Å |
| Aldolase | 156 kDa | 2.2 Å | 1.7 Å |
| Ubiquitin | 8.5 kDa | Not resolvable | 2.8 Å |
| Insulin hexamer | 34.8 kDa | Not resolvable | 3.1 Å |
The cryo-ET application — watching proteins inside live cells: Cryo-electron tomography (cryo-ET) tilts the sample to reconstruct a 3D image of the entire cellular environment. With the laser phase plate:
- Proteins as small as 10 kDa become visible inside cells (vs ~500 kDa previous limit in cellular context)
- This means: visualising signalling complexes, chaperones, and ubiquitin-proteasome pathways in situ without purification
- Drug discovery implication: see how drug candidate changes protein conformations inside live cells, not just in purified crystal
🧬 Pakistan Genome Resource — Human Knockouts as a Drug Discovery Shortcut
The Drug Target Validation Problem
Why most drugs fail in human trials despite animal model success:
| Development Stage | Attrition Rate | Primary Reason for Failure |
|---|---|---|
| Lead compound → animal model | 90% fail | Toxicity, poor pharmacokinetics |
| Animal model → Phase I (human safety) | 80% fail | Unexpected human toxicity |
| Phase I → Phase II (human efficacy) | 60% fail | No human efficacy (animal model didn't predict) |
| Phase II → Phase III | 50% fail | Insufficient efficacy at safe dose |
| Phase III → approval | 30% fail | Statistical/safety issues at scale |
| Overall: preclinical → approval | ~1 in 10,000 compounds | — |
The core problem: mouse knockouts (genetically engineered mice lacking specific genes) predict human biology poorly. Human knockouts (natural loss-of-function variants in humans) are the gold standard — but rare in any individual genome.
The Pakistan Genome Resource — Scale and Findings
Why Pakistan provides uniquely high knockout frequency: Pakistan has a high rate of consanguinity (marriage between relatives) — estimated 50–70% of marriages are between cousins. Consanguinity substantially increases homozygosity — the likelihood that both copies of a gene carry the same variant. A person who inherits the same loss-of-function variant from both parents becomes a natural knockout.
Pakistan Genome Resource (PGR) statistics:
| Metric | Value |
|---|---|
| Total individuals sequenced | 173,303 |
| Sequencing type | Exome (protein-coding) + whole genome (subset) |
| Unique genetic variants identified | ~1.2 million (many South Asia-specific) |
| Genes with identified knockouts | 6,496 out of ~19,000 protein-coding genes (34%) |
| Individuals who are knockout for ≥1 gene | ~35,000 (20% of cohort) |
| Previously uncharacterised gene knockouts | ~2,100 genes (new to science) |
Drug target validation using PGR — the key logic:
| Scenario | PGR Finding | Drug Development Implication |
|---|---|---|
| Target knocked out → healthy phenotype | Humans without this protein are completely healthy | Drug inhibiting this target is likely safe |
| Target knocked out → disease phenotype | Humans without this protein develop specific disease | Validates target for that disease; drug could activate/substitute |
| Target knocked out → lethal (no knockouts found) | Zero homozygous knockouts in 173K individuals | Drug inhibiting this target may be lethal; deprioritise |
| Mouse essential, human knockout healthy | Mouse KO lethal, human KO healthy (PGR data) | Mouse model not predictive; avoid mouse-based selection bias |
Specific validated discoveries from PGR:
| Gene | Knockout Phenotype | Drug Discovery Impact |
|---|---|---|
| PCSK9 | Knockouts: very low LDL cholesterol, healthy | Validated target for evolocumab/alirocumab (cholesterol drugs, already approved — retrospective validation) |
| ANGPTL3 | Knockouts: very low triglycerides, healthy | Validates ANGPTL3 inhibitors (in clinical trials) |
| MSTN (myostatin) | Knockouts: increased muscle mass, healthy | Validates myostatin inhibitors for muscle-wasting diseases |
| 3 novel cardiovascular genes | Knockouts: lower BP + LDL, healthy | New drug targets — pharmaceutical partners notified |
| 12 novel metabolic genes | Knockouts: no detectable disease | Potential safe targets for metabolic disease drugs |
📌 The Bottom Line
- goethe-nestar-gravastar-mini-universe: Singularity problem: GR predicts infinite density — must be wrong; gravastar = dark energy core (de Sitter interior, negative pressure) + thin matter shell; nestar = nested gravastars (Russian doll structure); stability range: 1.4–100 M☉; exterior = Schwarzschild metric (identical to BH; r=2GM/c²); no event horizon (resolves information paradox); interior de Sitter metric matches FLRW cosmology = isotropic expanding mini-universe; GW echo prediction: t ≈ 0.1-1 × 10⁶ × r_s/c after merger → potentially detectable by LISA.
- berkeley-laser-phase-cryo-em: 90% of human proteome (<70 kDa) previously invisible; laser phase plate: 1,064nm CW + F>100,000 Fabry-Pérot cavity (~1 MW/cm² intracavity) at 10μm waist; π/2 phase shift to unscattered beam (no material in beam = no charging/degradation); results: ubiquitin 8.5 kDa at 2.8Å (first ever), insulin 34.8 kDa at 3.1Å, haemoglobin 64 kDa 3.4→1.9Å; cryo-ET application: proteins as small as 10 kDa visible in situ inside live cells; drug discovery: see conformational changes from drug candidates inside cells, not purified crystals.
- pakistan-genome-resource-knockouts: 173,303 individuals; consanguinity 50-70% → high homozygosity; 6,496 genes with knockouts (34% of proteome); 35,000 individuals (20%) knockout for ≥1 gene; 2,100 novel gene knockouts; validation logic: healthy KO → safe to inhibit; disease KO → valid target; no KO found → likely lethal to inhibit; specific findings: PCSK9 KO validates evolocumab (retrospective), ANGPTL3 KO validates clinical trials ongoing, MSTN KO validates muscle-wasting target; 3 novel cardiovascular + 12 novel metabolic targets identified.
📬 Stay Updated
Get the week's biggest science and space discoveries delivered to your inbox. Subscribe to our free newsletter →
Disclosure: This post contains affiliate links. If you purchase through our links, we earn a small commission at no extra cost to you. We only recommend products we believe in.
Enjoyed this post?
Get our weekly digest delivered free.
Share this post:
Knowelth is reader-supported. We may earn a commission from links in this article at no extra cost to you. Read our disclosure.


